Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Raw Materials (2022 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Raw Materials for 4 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Raw Materials rose 1.18% to $3.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 million, a 1.18% increase, with the full-year FY2025 number at $3.6 million, up 1.18% from a year prior.
  • Raw Materials was $3.6 million for Q4 2025 at Ekso Bionics Holdings, down from $3.8 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $4.3 million in Q4 2023 to a low of $3.6 million in Q4 2024.
  • A 4-year average of $3.9 million and a median of $4.0 million in 2024 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: grew 12.01% in 2023, then decreased 17.38% in 2024.
  • Ekso Bionics Holdings' Raw Materials stood at $3.8 million in 2022, then rose by 12.01% to $4.3 million in 2023, then fell by 17.38% to $3.6 million in 2024, then increased by 1.18% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Raw Materials are $3.6 million (Q4 2025), $3.8 million (Q3 2025), and $4.0 million (Q2 2025).